389650
Next Biomedical Co.,Ltd. engages in the research and development, production, and development of therapeutics, drug delivery system and drug-medical device products in South Korea. It offers hemostatic material for endoscope; and microspheres for vascular embolization. The company was founded in 2014 and is based in Incheon, South Korea.
389650 (389650) - Total Liabilities
Latest total liabilities as of September 2025: ₩11.84 Billion KRW
Based on the latest financial reports, 389650 (389650) has total liabilities worth ₩11.84 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
389650 - Total Liabilities Trend (2021–2024)
This chart illustrates how 389650's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
389650 Competitors by Total Liabilities
The table below lists competitors of 389650 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Runben Biotechnology Co Ltd Ordinary Shares - Class A
SHG:603193
|
China | CN¥134.06 Million |
|
338840
KQ:338840
|
Korea | ₩3.17 Billion |
|
Tristel PLC
PINK:TSNLF
|
USA | $11.88 Million |
|
ADVA Optical Networking SE
PINK:ADVOF
|
USA | $270.47 Million |
|
Heba Fastighets AB Series B
LSE:0GNV
|
UK | Skr8.00 Billion |
|
Black Box Limited
NSE:BBOX
|
India | ₹-7.59 Billion |
|
Mennica Polska S.A.
WAR:MNC
|
Poland | zł1.28 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down 389650's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.64 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 389650's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 389650 (2021–2024)
The table below shows the annual total liabilities of 389650 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩13.65 Billion | -61.59% |
| 2023-12-31 | ₩35.54 Billion | +9.74% |
| 2022-12-31 | ₩32.39 Billion | -6.49% |
| 2021-12-31 | ₩34.64 Billion | -- |